Publications

by | October 3, 2014 | Uncategorized

Evaluation | European Parliament hearing – Elzbieta Bienkowska European Commissioner-designate for Internal Market, Industry, Entrepreneurship and SMEs

“Placing pharma policy in DG Enterprise was justified. It has traditionally been in DG Enterprise, but was moved to DG Sanco and has once again been instated as an Enterprise competence” said during her hearing Commissioner-designate Elzbieta Bienkowska.

By Dorota Sienkiewicz, Health Equity and Policy Coherence Coordinator, and Martyna Giedrojć, EPHA Policy Officer for Health Systems

The pharmaceutical industry is the biggest sector in the world. In terms of production, the EU occupies third place when it comes to export of medicines worldwide. This sector is highly innovative, which is why it makes sense to place it within DG Enterprise, claimed Bienkowska. During her hearing, she stressed that people’s health, consumer satisfaction and quality of medicines were at the forefront of her mind. When asked by MEP DeJong if she was willing to send a letter to President Juncker to advise for the move to be re-considered, she declined as, in her opinion, the move was “fully justified”.

MEP Piecha asked a question about increasing prices and difficulties in the legislation of new drugs. He suggested that moving pharma policy would cause an imbalance in access to medicines. Bienkowska replied that she doesn’t have any experience in the pharma industry but that itself is not a problem, because her team would take care of that. Currently, however, she doesn’t yet know who would be responsible for pharma policy. Interestingly, she praised herself for being “totally and absolutely immune to lobbying”, a statement to be surely closely monitored by corporate lobbying watchdogs in the EU.

Bienkowska promised that the health safety of patients and access to and quality of medicines would be provided, independently and regardless of which portfolio pharma is included.

MEP Backer raised the issue about delays in access to new medicines in Member States. In a question from MEP Willmott, relating to clinical data transparency, Bienkowska was likewise confident in being fully capable of dealing with the issue.

In conclusion, Bienkowska seems to have a long list of priorities to focus on, where ensuring favourable conditions for the industry strongly came forward. She seemed to acknowledge the social dimension of the European economy and industry, but many of her messages were contradictory, leaving the public health community unconvinced that under her watch, the pharmaceutical industry and the control of European Medicine Agency will not hamper patients’ rights and access to medicines. In addition, she made reference to health without any definition of whether she meant ‘health and safety’ or health, and safety.

Ms Bienkowska is committed to cutting red tape (although she was unable to provide any concrete examples as to which legislative acts she would remove); lessen administrative burdens for industry as a whole and SMEs in particular; and better allocate and fully use European funds in areas where they are most needed. She promised to take into account the social clause and all possible ex-ante & ex-post evaluations of EU industrial policies in line with the Treaty.

More information and input from social media:

Introductory Statement to the European Parliament by Commissioner-designate Elżbieta Bieńkowska – Internal Market, Industry, Entrepreneurship and SMEs –

“At the same time, let it be clear that in working with Europe’s industrial sectors, I will act with particular precaution in areas of citizens concern.
First in the health products sector, let me assure you that guaranteeing the health of our patients and citizens’ will be my full and leading concern. Health and safety come first! And I intend to closely work on all health matters with my colleague Vytenis Andriukaitis, the designated Commissioner for Health.”

Marc Tarabella (@marctarabella)
#Bienkowska refuse de retrocéder le domaine médicament à la DG sanco. Triste: pour ns, les médicaments ne sont pas de simples marchandises! (https://twitter.com/marctarabella/status/517655454840025088)

Françoise Grossetête (‏@GrosseteteF)
#Bieńkowska says she will put patients safety 1st & work with Health Comm. on pharma legislation. Shuts down useless polemics#EPHearing2014

Louis Ide (@louis_ide)
To #Bienkowska there is no problem that #pharmaceutical #health issues become her competency #shame @ecrgroup #EPhearings2014 @de_NVA (https://twitter.com/louis_ide/status/517652516809760768)

Ilaria Passarani (@IlariaPassarani)
#Bienkowska #EPhearings2014 Piecha MEP asks:”how can we reduce the power gap between the pharma industry and the users of medicines”? (https://twitter.com/IlariaPassarani/status/517664849225342976)

– Follow the latest developments on #Pharma4health

—–
Related EPHA articles
—–

  • [->6179]
  • [->6177]
  • [->6175]
  • [->6173]
  • [->6157]
  • [->6155]
  • [->6153]
  • [->6152]
  • [->6140]
  • [->6135]

—–
Other media commenting on this issue:
—–

Get the EPHA Newsletter

The best of our activities, right in your inbox!